AKP-11 is under clinical development by Akaal Pharma and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect AKP-11’s likelihood of approval (LoA) and phase transition for Osteoarthritis took place on 20 Nov 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AKP-11 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

AKP-11 overview

AKP-11 is under development for the treatment of pain and inflammation associated with arthritis, autoimmune diseases, pruritus, acne vulgaris, gout, alopecia areata and neuropathy pain, atopic dermatitis, mild to moderate plaque psoriasis. The drug candidate is administered both topically and orally. It is a small molecule acts by targeting sphingosine-1-phosphate (S1P) receptor 1. It is developed based on drug design and discovery technology platform. It was also under development for the treatment of multiple sclerosis and ulcerative colitis.

It was also under development for the treatment of diabetic retinopathy.

Akaal Pharma overview

Akaal Pharma is a clinical-stage drug discovery and development company that focus on developing small molecule drugs for the treatment of autoimmune, inflammatory and pain indications. It offers drugs candidate, which is used in the treatment of psoriasis, atopic dermatitis, multiple sclerosis, ulcerative colitis and rheumatoid arthritis. Akaal Pharma works in partnership with pharmaceutical and biotechnology companies to develop for the treatment of various inflammatory and autoimmune diseases. The company also provides clinical studies and clinical trial services. Akaal Pharma is headquartered in Melbourne, Victoria, Australia.

Quick View AKP-11 LOA Data

Report Segments
  • Innovator
Drug Name
  • AKP-11
Administration Pathway
  • Oral
  • Topical
Therapeutic Areas
  • Central Nervous System
  • Dermatology
  • Gastrointestinal
  • Immunology
  • Metabolic Disorders
  • Musculoskeletal Disorders
Key Developers
  • Sponsor Company: Akaal Pharma
  • Originator: Akaal Pharma
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.